A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica
Status:
Completed
Trial end date:
2020-02-25
Target enrollment:
Participant gender:
Summary
This is an open-label study that will evaluate the safety of PCS499 for the treatment of
necrobiosis lipoidica (NL) and will inform the design of future studies. Approximately 12 NL
patients (6-9 patients without ulceration and 3-6 patients with ulceration) who also meet
other inclusion/exclusion criteria will be enrolled in the study. The primary objective of
this study is to evaluate the safety and tolerability profile of PCS499 in patients with
Necrobiosis Lipoidica.